@GynCancerMD
Epithelial ovarian cancer and other related types can grow resistant to platinum chemotherapy, but a recently approved targeted therapy appears to boost the chemotherapy’s effectiveness. Learn more: brnw.ch/21x6nhZ @AngelesSecord @GynCancerMDView quoted post on X
Register via this link ⬇️ : ovarcome.org/ovarcoming-can…
Our 14th Annual Global Conference is on September 17-18.
We are honored to announce our third Speaker, Dr. @GynCancerMD! One of the leading global experts in Low Grade Serous Ovarian Cancer, Dr. Slomovitz has been at the forefront of practice changing pivotal trials to improve outcomes for the LGSOC community. 🙏🏼
Dr. Slomovitz will be joining us to Talk About Rare Ovarian Cancers: Progress, Advances & Hope Ahead.
Join us for our 2 day Annual Conference and please share with anyone who may benefit - it is FREE, as knowledge should be!
Dr. Slomovitz invites you! 🩵
Ask. Learn. Share. Be EMPOWERED!
#OvarCon2026View quoted post on X
🔬 Ahead of #SGO2026 , experts highlight the presentations they’re most excited about:
@DrMaurieMarkman: FDA therapy & early-phase trial updates
@GynCancerMD: Ongoing ovarian, uterine & cervical cancer studies
📈 Get the full preview:
hubs.li/Q04b4Gj-0View quoted post on X
www.targetedonc.com Beyond Chemotherapy: Evaluating the Efficacy of Ribociclib, Letrozole in LGSOC | Targeted Onc -... Researchers explore a promising nonchemotherapy treatment for low-grade serous ovarian cancer, combining ribociclib and letrozole to improve patient outcomes. 
aacrjournals.org Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical... Abstract. Endometrial cancer incidence and mortality are rising globally, largely driven by the obesity epidemic. Treatment options remain limited for obesity-associated, hormone-resistant, or... 
